Pharmacological evaluation of benzimidazole derivatives with potential antiviral and antitumor activity

被引：21

作者：

Abu-Bakr, Sherifa M. ^{[2
]}

Bassyouni, Fatma A. ^{[1
]}

Rehim, Mohamed Abdel ^{[3
]}

机构：

[1] Natl Res Ctr, Dept Chem Nat & Microbial Prod & Pharmaceut Res, Ctr Excellence Adv Sci, Cairo 12622, Egypt

[2] Natl Res Ctr, Dept Chem Nat & Microbial Prod, Cairo 12622, Egypt

[3] Stockholm Univ, Dept Analyt Chem, S-10691 Stockholm, Sweden

来源：

RESEARCH ON CHEMICAL INTERMEDIATES | 2012年 / 38卷 / 09期

关键词：

Benzimidazole derivatives; Combinatorial synthesis; Microwave-assisted synthesis; Heterocycles; Topoisomerase inhibitors; Protein kinase inhibitor; Antitumor; Antiviral; RNA-POLYMERASE INHIBITORS; ANTI-HIV ACTIVITY; SELECTIVE INHIBITOR; KINASE; VIRUS; IDENTIFICATION; OPTIMIZATION; DISCOVERY; BEARING;

D O I：

10.1007/s11164-012-0569-y

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

In recent years the synthesis of benzimidazole and its derivatives has attracted the attention of many organic chemists because of the compounds' interesting biological activity and the crucial importance of the benzimidazole unit in the function of these biologically important molecules. Benzimidazole-based polyheterocyclic compounds have several interesting biological properties. Simple synthetic strategies leading to benzimidazole-based fused polyheterocyclic systems and the antiviral and anticancer biological activity of the compounds are surveyed in this review article.

引用

页码：2523 / 2545

页数：23

共 75 条

[1] Benzimidazole condensed ring systems: New synthesis and antineoplastic activity of substituted 3,4-dihydro- and 1,2,3,4-tetrahydro-benzo[4,5]imidazo[1,2-a]pyrimidine derivatives [J].

Abdel-hafez, Atef Abdel-monem .

ARCHIVES OF PHARMACAL RESEARCH, 2007, 30 (06) :678-684

[2]

Abraham D., 2003, BURGERS MED CHEM DRU, V5, P124

[3]

Alamgir M, 2007, TOP HETEROCYCL CHEM, V9, P87, DOI 10.1007/7081_2007_088

[4]

Alper Sabiha, 2003, Farmaco (Lausanne), V58, P497, DOI 10.1016/S0014-827X(03)00042-9

[5] Substituted benzimidazoles with nanomolar activity against respiratory syncytial virus [J].

Andries, K ;

Moeremans, M ;

Gevers, T ;

Willebrords, R ;

Sommen, C ;

Lacrampe, J ;

Janssens, F ;

Wyde, PR .

ANTIVIRAL RESEARCH, 2003, 60 (03) :209-219

[6] Synthesis, antiprotozoal and anticancer activity of substituted 2-trifluoromethyl- and 2-pentafluoroethylbenzimidazoles [J].

Andrzejewska, M ;

Yépez-Mulia, L ;

Cedillo-Rivera, R ;

Tapia, A ;

Vilpo, L ;

Vilpo, J ;

Kazimierczuk, Z .

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2002, 37 (12) :973-978

[7] Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles [J].

Arienti, KL ;

Brunmark, A ;

Axe, FU ;

McClure, K ;

Lee, A ;

Blevitt, J ;

Neff, DK ;

Huang, LM ;

Crawford, S ;

Pandit, CR ;

Karlsson, L ;

Breitenbucher, JG .

JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (06) :1873-1885

[8] Quinazoline and benzimidazole MCH-1R antagonists [J].

Arienzo, Rosa ;

Cramp, Sue ;

Dyke, Hazel J. ;

Lockey, Peter M. ;

Norman, Dennis ;

Roach, Alan G. ;

Smith, Phil ;

Wong, Melanie ;

Wren, Stephen P. .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (05) :1403-1407

[9] The specificities of protein kinase inhibitors: an update [J].

Bain, J ;

McLauchlan, H ;

Elliott, M ;

Cohen, P .

BIOCHEMICAL JOURNAL, 2003, 371 :199-204

[10]

Barreca L.M., 2003, FARMACO, V58, P259

← 1 2 3 4 5 6 7 8 →